Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes

Journal of Diabetes Investigation

Volumn 8, Issue 4, 2017, Pages 431-433

  Kim, Hae Jin ^a   Kim, Dae Jung ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; EXENDIN 4; LIRAGLUTIDE; PLACEBO; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; WEIGHT REDUCTION; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC ANGIOPATHY; METHODOLOGY; STANDARDS; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85011655558     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12607     Document Type: Note

References (9)

1. Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147: 149–155.
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring: FDA, 2008.
3. Avogaro A, Fadini GP, Sesti G, et al. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol 2016; 15: 111.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
6. Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 2014; 63: 3346–3358.
7. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–2257.
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834–1844.
9. Holman RR, Bethel MA, George J, et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 2016; 30: 103–110.